Numerous novel HER2-targeted drugs are currently under development, including Pertuzumab, Margetuximab, Zanidatamab (ZW25), KN026 (a HER2 bispecific antibody),Tyrosine kinase inhibitors (TKIs),as well as Antibody Drug Conjugates like Trastuzumab Emtansine (T-DM1), Trastuzumab Deruxtecan (T-DXd), and Disitamab Vedotin (RC48).These drugs all exhibit certain therapeutic efficacies in the treatment of gastric cancer (Table 1). Here, ERBB2 is linked to gastric cancer.